ADVFN Logo
Boards:
    Quotes:
      Boards
      News
      Market Data
      Markets
      Discover
      AI Subscribe Login/Register Profile Icon
      S&P 500
      5,815.03
      0.61%
      US Tech 100
      19,700.96
      -0.01%
      Dow Jones
      42,863.86
      0.97%
      Brent Oil
      78.695
      0.00%
      Bitcoin
      62,700.09
      0.41%
      Registration Strip Icon for discussion Register to chat with like-minded investors on our interactive forums.
      Get Started
      1. Home
      2. Investing
      3. Stocks
      4. USA
      5. NASDAQ

      6. AtriCure Inc (ATRC) Quote

      AtriCure Inc

      AtriCure Inc (ATRC)

      NASDAQ
      27.84
      0.79
      (2.92%)
      Closed October 11 4:00PM
      Delayed by 15 minutes
      27.84
      -0.02
      (-0.07%)
      After Hours: 6:09PM
      Delayed by 15 minutes

      Empower your portfolio: Real-time discussions and actionable trading ideas.

      Premium

      Key stats and details

      Current Price
      27.84
      Bid
      27.36
      Ask
      28.22
      Volume
      489,021
      26.92 Day's Range 27.93
      18.94 52 Week Range 42.9999
      Market Cap
      1.356B
      Previous Close
      27.05
      Open
      27.01
      Last Trade
      70
      @
      27.84
      Last Trade Time
      Financial Volume
      $ 13,479,974
      VWAP
      27.5652
      Average Volume (3m)
      666,919
      Shares Outstanding
      48,697,505
      Dividend Yield
      -
      PE Ratio
      -44.58
      Earnings Per Share (EPS)
      -0.63
      Revenue
      399.25M
      Net Profit
      -30.44M

      About AtriCure Inc

      AtriCure Inc is a innovator in surgical treatments and therapies for atrial fibrillation (Afib), left atrial appendage (LAA) management and post-operative pain management and sells its products to medical centers through its direct sales force and distributors. Its product line includes Cryo, Soft T... AtriCure Inc is a innovator in surgical treatments and therapies for atrial fibrillation (Afib), left atrial appendage (LAA) management and post-operative pain management and sells its products to medical centers through its direct sales force and distributors. Its product line includes Cryo, Soft Tissue Dissection, RF Ablation Pacing and Sensing, and others. The company also offers a variety of minimally invasive ablation devices and access tools to facilitate the growing trend in less invasive cardiac and thoracic surgery. Geographically, it generates a majority of its revenue from the United States. Show more

      Sector
      Surgical,med Instr,apparatus
      Industry
      Surgical,med Instr,apparatus
      Website
      www.atricure.com
      Headquarters
      Wilmington, Delaware, USA
      Founded
      -
      AtriCure Inc is listed in the Surgical,med Instr,apparatus sector of the NASDAQ with ticker ATRC. The last closing price for AtriCure was $27.05. Over the last year, AtriCure shares have traded in a share price range of $ 18.94 to $ 42.9999.

      AtriCure currently has 48,697,505 shares outstanding. The market capitalization of AtriCure is $1.32 billion. AtriCure has a price to earnings ratio (PE ratio) of -44.58.

      Ask ADVFN Intelligence (AI)

      ATRC Latest News

      More News

      AtriCure to Announce Third Quarter 2024 Financial Results

        AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in surgical treatments and therapies for atrial fibrillation (Afib), left atrial appendage (LAA) management, and post-operative pain...

      October 08 2024
      Business Wire

      AtriCure a obtenu la certification de marquage CE pour la pince EnCompass®

      Une approbation qui sert de nouveau vecteur de croissance à l'international pour AtriCure AtriCure, Inc. ( Nasdaq: ATRC ), leader en matière d'innovation pour les interventions chirurgicales et...

      October 01 2024
      Business Wire

      AtriCure erhält CE-Kennzeichnung für die EnCompass®-Klemme

      Die Zulassung ist ein neuer Katalysator für das internationale Wachstum von AtriCure AtriCure, Inc. (Nasdaq: ATRC), ein führender Innovator im Bereich chirurgischer Behandlungen und Therapien...

      October 01 2024
      Business Wire

      AtriCure Receives CE-Mark for the EnCompass® Clamp

      Approval provides new catalyst for AtriCure’s international growth AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in surgical treatments and therapies for atrial fibrillation (Afib), left...

      October 01 2024
      Business Wire

      Form 4 - Statement of changes in beneficial ownership of securities

      September 18 2024
      Edgar (US Regulatory)

      AtriCure Announces that the First Patient has been Treated with the Revolutionary AtriClip® FLEX-Mini™ Device

      AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in surgical treatments and therapies for atrial fibrillation (Afib), left atrial appendage (LAA) management, and post-operative pain management...

      August 27 2024
      Business Wire

      AtriCure bénéficie d'une indication élargie du marquage CE pour les dispositifs AtriClip ® qui permettent de réduire les accidents vasculaires cérébraux chez les patients souffrant de fibrillation auriculaire

      Une indication élargie avec abondance de preuves cliniques à l'appui pour les dispositifs AtriClip AtriCure, Inc. ( Nasdaq : ATRC ), l'un des principaux innovateurs dans le domaine des...

      August 22 2024
      Business Wire

      AtriCure erhält eine erweiterte CE-Kennzeichnung für AtriClip®-Geräte zur Reduzierung von Schlaganfällen bei Patienten mit Vorhofflimmern

      Erweiterte Indikation auf Basis von zahlreichen klinischen Nachweisen für AtriClip-Geräte AtriCure, Inc. (Nasdaq: ATRC), ein führender Innovator im Bereich chirurgischer Behandlungen und...

      August 22 2024
      Business Wire

      AtriCure Receives Expanded CE-Mark Indication for AtriClip® Devices for the Reduction of Stroke in Patients with Atrial Fibrillation

      Expanded indication based on an abundance of clinical evidence for AtriClip Devices AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in surgical treatments and therapies for atrial fibrillation...

      August 22 2024
      Business Wire

      Form 4 - Statement of changes in beneficial ownership of securities

      August 19 2024
      Edgar (US Regulatory)
      PeriodChangeChange %OpenHighLowAvg. Daily VolVWAP
      10.110.39668229354527.7328.2226.6244529327.20940577CS
      4-0.15-0.535905680627.9930.1526.6254235728.10579226CS
      123.1112.575818843524.7330.1520.266691924.69303967CS
      261.676.3813526939226.1730.1518.9477332823.53219169CS
      52-13.05-31.91489361740.8942.999918.9468866528.12046797CS
      156-42.97-60.683519276970.8189.1818.9441831237.86614423CS
      2602.419.476995674425.4389.1818.9439014542.45124705CS

      Movers

      View all
      • Most Active
      • % Gainers
      • % Losers
      SymbolPriceVol.
      CAMPCAMP4 Therapeutics Corporation
       10.75
      (2,587.50%)
      		378.47k
      TWGTop Wealth Group Holding Ltd
      $ 7.14
      (233.64%)
      		149.99M
      NIVFNewGenIvf Group Ltd
      $ 0.98
      (63.42%)
      		57.16M
      ATIFATIF Holdings Ltd
      $ 1.235
      (58.33%)
      		3.85M
      VERBVerb Technology Company Inc
      $ 7.91
      (51.82%)
      		15.55M
      BYUBAIYU Holdings Inc
      $ 0.299
      (-35.28%)
      		11.1M
      TURBTurbo Energy SA
      $ 2.1511
      (-29.01%)
      		3.2M
      SMSTDefiance Daily Target 1.5X Short MSTR ETF
      $ 7.898
      (-23.62%)
      		993.32k
      VEEAVeea Inc
      $ 3.27
      (-23.24%)
      		284.95k
      INHDInno Holdings Inc
      $ 3.74
      (-22.41%)
      		257.75k
      JTAIJet AI Inc
      $ 0.1009
      (23.50%)
      		335.77M
      CDTConduit Pharmaceuticals Inc
      $ 0.116
      (13.28%)
      		257.95M
      NVDANVIDIA Corporation
      $ 134.80
      (-0.01%)
      		161.76M
      LUXHLuxUrban Hotels Inc
      $ 0.0532
      (5.35%)
      		159.27M
      TWGTop Wealth Group Holding Ltd
      $ 7.14
      (233.64%)
      		149.99M

      ATRC Discussion

      View Posts
      mlkrborn mlkrborn 11 years ago
      HISTORY
      Initial Public Offering



      On August 10, 2005, we consummated an initial public offering of 4.6 million shares of our common stock at $12.00 per share, which includes the underwriters exercise of their over-allotment option, on August 9, 2005, to purchase 600,000 shares of our common stock of which 450,000 shares were sold by selling shareholders and 150,000 shares were sold by us. We did not receive any proceeds from the sale of the 450,000 shares of common stock that were sold by selling shareholders. These share amounts reflect a 1-for-3.8 reverse split of our capital stock that was effected on July 27, 2005. Proceeds to us from the offering, after deducting underwriting discounts and commissions but before expenses, were $46.3 million. Expenses are estimated to be approximately $3.25 million.



      15
      👍️0
      mlkrborn mlkrborn 11 years ago
      AtriCure receives FDA approval for investigational study to evaluate stroke prevention in atrial fibrillation (ATRC) 14.35 : Co announces the FDA approval to begin enrollment in a clinical study of AtriCure's AtriClip Left Atrial Appendage Exclusion System. The study will evaluate the use of the AtriClip device to prevent stroke in patients with Afib. The feasibility study will enroll Afib patients at seven medical centers across the country. The study will focus on patients with risk factors that place them at significant risk of stroke as well as substantial bleeding risks that contraindicate them for anticoagulation therapy. Research suggests that up to 40% of patients are unable to take oral anticoagulants due to excessive risk of bleeding.
      👍️0
      dmarkg dmarkg 12 years ago
      Hey Wobblenuts and Jackie Scan I want to show you something....

      Medical Breakthrough Wound Stasis Technology

      ATRC and EPGL could possibly go hand in hand here...
      Merry Christmas 2012

      Merry Chirstmas 2012, friends.
      👍️0
      wobblenuts wobblenuts 12 years ago
      Any talks involving ATRC and soon to be sub penny wonder EPGL?



      Are they hinting at something here?


      1)"ATRC fully SEC reporting financials are available at OTCMARKETS for EPGL investors to see as an example of where EPGL management is headed."

      2)"EPGL initiating R&D on 4 new medical devices before end of 2012."

      3)"Property and equipment, net 0"
      👍️0
      Penny Roger$ Penny Roger$ 13 years ago
      ~ Monday! $ATRC ~ Earnings posted, pending or coming soon! In Charts and Links Below!

      ~ $ATRC ~ Earnings expected on Monday *
      Want more like this? Search Keyword: MACMONEY >>> http://tinyurl.com/MACMONEY <<<
      One or more of many earnings sites has alerted this security has or will be posting earnings on or around the day of this message.








      http://stockcharts.com/h-sc/ui?s=ATRC&p=D&b=3&g=0&id=p88783918276&a=237480049




      http://stockcharts.com/h-sc/ui?s=ATRC&p=W&b=3&g=0&id=p54550695994



      ~ Google Finance: http://www.google.com/finance?q=ATRC
      ~ Google Fin Options: hhttp://www.google.com/finance/option_chain?q=ATRC#
      ~ Yahoo! Finance ~ Stats: http://finance.yahoo.com/q/ks?s=ATRC+Key+Statistics
      ~ Yahoo! Finance ~ Profile: http://finance.yahoo.com/q/pr?s=ATRC
      Finviz: http://finviz.com/quote.ashx?t=ATRC
      ~ BusyStock: http://busystock.com/i.php?s=ATRC&v=2


      <<<<<< http://www.earningswhispers.com/stocks.asp?symbol=ATRC >>>>>>



      http://investorshub.advfn.com/boards/post_prvt.aspx?user=251916

      *If the earnings date is in error please ignore error. I do my best.
      👍️0
      Penny Roger$ Penny Roger$ 13 years ago
      AtriCure, Inc., is a medical device company. The Company develops, manufactures and sells cardiac surgical ablation systems designed to create lesions, or scars, in cardiac, or heart, tissue and devices for the exclusion of the left atrial appendage. The Company has two primary product lines for the ablation of cardiac tissue. Its primary product line, which accounts for a majority of its revenues, is Isolator Synergy bipolar ablation clamp system (Isolator system) and related radiofrequency ablation devices. It also offers a cryoablation product line, which features reusable and disposable cryoablation devices. In addition, it offers the AtriClip Gillinov-Cosgrove Left Atrial Appendage System, or AtriClip system, which is designed to exclude the left atrial appendage.

      http://www.google.com/finance?q=ATRC
      👍️0

      Your Recent History

      NASDAQ
      ATRC
      AtriCure
      Delayed Upgrade Clock